report_lead_image_with_gradient.png
Q1 2026

Pharma Biotools VC Trends

Download this Report
To download this report, please complete the form below

PitchBook clients can access the full report and Excel data pack via the Research Center on the PitchBook Platform.

Pharma biotools deal counts surge past pandemic highs as services lead Q1 2026

VC-backed pharma biotools companies raised $1.1 billion across 122 deals in Q1 2026, sustaining the near-record deal count pace set in 2025. The services segment led deal value at $376 million, headlined by Cellares’ $257 million raise to scale automated cell therapy manufacturing. Platforms & reagents and in silico discovery followed closely, with Nuclera ($87 million) and Antheia ($80 million) among the quarter’s largest rounds. Exit activity was quiet, with five completed transactions and only one disclosed value—bioMérieux’s $50 million acquisition of Accellix.

The bigger story is structural. In 2025, early-stage VC funding in AI-native pharma biotools companies surpassed non-AI-native investment for the first time, and deal counts surged across nearly every segment. But the expansion is not just an AI story. Services posted the highest deal count growth at nearly 60% YoY, and regional analysis reveals a widening gap between North America’s tilt toward asset-light software models and Asia’s continued focus on capital-intensive infrastructure. As AI-accelerated discovery expands the pool of drug candidates entering the pipeline, the bottleneck is shifting from discovery to development—a dynamic that could reshape where investors place their next bets across the pharma biotools vertical.


In 2025, early-stage VC funding in AI-native pharma biotools companies outpaced non-AI-native investment for the first time, and the trend continued in Q1 2026.


Table of contents
Pharma biotools landscape 3
Quarterly analysis 4
       Key takeaways 4
       Vertical overview 4
       VC activity 6
       Segment-level and regional trends 8
       AI themes 10
       Other notable events 11
       Conclusions 11
Pharma biotools VC deal summary 34
References 35